1. At a Glance – The ₹190 Cr Chemical Cocktail
At ₹67 per share and a market cap of ₹190 crore, Aarey Drugs & Pharmaceuticals Ltd is currently trading at a P/E of 55.4 while delivering an OPM of -0.35% and ROE of just 2.96%. Yes, you read that correctly. Fifty-five times earnings for a company that makes less than 1% net margin.
Q3 FY26 (Dec 2025 quarter) sales came in at ₹96.43 crore, down 27.9% YoY and PAT at ₹0.57 crore, down 20.8% YoY.
Three-month return? -31%.
One-year return? +50%.
Welcome to smallcap pharma where logic takes coffee breaks.
Debt stands at ₹50.8 crore, debt-to-equity at 0.34, and promoter holding has slipped to 39.05%. They even paid a fine of ₹5,900 to each exchange for delayed related party disclosure. Premium compliance vibes.
So here’s the big question:
Is this a hidden turnaround API play or just another “profit-on-paper, cash-in-the-void” chemical story?
Let’s dissect.
2. Introduction – The Curious Case of Thin Margins
Incorporated in 1990, Aarey Drugs manufactures APIs, intermediates, specialty chemicals, and trades industrial solvents. Basically, if it smells like a chemical and burns your nostrils, they probably sell it.
But here’s the spicy part.
Revenue in FY25 stood at ₹474 crore. TTM revenue? ₹391 crore. That’s a 32% contraction.
Profit growth over 3 years? -15%.
ROE over 3 years? 3%.
Yet, stock price CAGR over 3 years? 28%.
This is what happens when markets trade hope, not margins.
And remember — earnings include ₹14.1 crore of other income in TTM. When your operating margin is negative and other income is doing heavy lifting, it’s like a student passing exams because of internal marks.
But wait — debtor days improved from 170 to 103. That’s real progress. Cash discipline matters.
So is management cleaning up? Or just surviving?
3. Business Model
